These results provide insights into the potential strategies for advanced CRC, such as administering histone demethylase inhibitors to suppress the activation of ARID3B-mediated target genes or administering ICIs to eliminate PD-L1-expressing CRCSCs. The gene discussed is ARID3B; the disease is colorectal carcinoma.